ACHV - Achieve Life Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9300
-0.0200 (-1.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9500
Open1.9600
Bid1.9000 x 800
Ask2.0000 x 900
Day's Range1.9300 - 2.1000
52 Week Range1.0400 - 5.2500
Volume152,535
Avg. Volume246,769
Market Cap15.103M
Beta (3Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
    PR Newswire27 days ago

    Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

    SEATTLE, Wash. and VANCOUVER, British Columbia, June 21, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14, 2019. The abstract "A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers" and oral presentation will include updated cytisinicline data from the recently completed ORCA-1 trial. Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.

  • Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
    PR Newswirelast month

    Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

    SEATTLE and VANCOUVER, British Columbia, June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced positive results from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. The primary endpoint was the reduction in daily smoking, a self-reported measure. Three of the four cytisinicline treatment arms demonstrated a statistically significant improvement, as defined in the protocol as p

  • PR Newswirelast month

    Achieve Receives $4.2 Million from Exercise of Warrants

    SEATTLE and VANCOUVER, British Columbia, June 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it entered into an agreement with a single investor to exercise outstanding warrants that will provide an aggregate of $4.2 million in total proceeds. The proceeds from the warrant exercise would bring Achieve's pro-forma cash balance to approximately $13.9M as of March 31, 2019, based on its most recently reported financial results. Pursuant to the agreement, the investor agreed to exercise outstanding warrants to purchase 270,313 shares of the Company's common stock, with an exercise price of $3.1445 per share and outstanding warrants to purchase 837,500 shares of Common Stock with an exercise price of $4.00 per share.

  • Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
    PR Newswire2 months ago

    Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline

    SEATTLE and VANCOUVER, British Columbia, May 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (No. 10,300,050) on succinate salt of cytisinicline and use thereof. Applications are pending in the European Patent Office, Japan, China, Australia, Canada, and South Korea. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.

  • Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
    CNW Group2 months ago

    Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update

    Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update

  • Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
    PR Newswire2 months ago

    Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019

    SEATTLE and VANCOUVER, British Columbia , May 7, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
    PR Newswire3 months ago

    Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

    SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications.

  • Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
    PR Newswire3 months ago

    Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019

    SEATTLE, Wash. and VANCOUVER, British Columbia , April 3, 2019 /PRNewswire/ --   Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development ...

  • Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
    PR Newswire4 months ago

    Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

    SEATTLE and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the Data Safety Monitoring Committee (DSMC) met on March 28, 2019 to conduct its second and final safety review of the ORCA-1 Trial. The DSMC is an independent committee that advises on continuation or stopping of clinical trials based upon safety and study conduct considerations. The ORCA-1 DSMC has had the responsibility for safeguarding the interests of trial subjects by assessing the safety of the interventions and monitoring the conduct of the ORCA-1 trial.

  • ACCESSWIRE4 months ago

    What Do the Clinical Updates at Achieve Life Sciences Mean for Cytisinicline

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on Achieve Life Sciences, Inc. (ACHV), a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic. On March 14th, the company provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. 2018 was a remarkable year of executing on the development plan for cytisinicline as a treatment for nicotine addiction and as an aid to smoking cessation.

  • Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
    PR Newswire4 months ago

    Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019

    SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Picking Up Speed On Friday

    CORAL GABLES, FL / ACCESSWIRE / March 15, 2019 / The future successes of the healthcare stock market are intrinsically entwined with whether, or not, healthcare companies are aptly prepared to rise to ...

  • Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
    PR Newswire4 months ago

    Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update

    SEATTLE and VANCOUVER, British Columbia , March 14, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
    PR Newswire4 months ago

    Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019

    SEATTLE and VANCOUVER, British Columbia , March 5, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • GlobeNewswire5 months ago

    Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.

  • ACCESSWIRE5 months ago

    Healthcare Stocks Leading the Sector

    HENDERSON, NV / ACCESSWIRE / February 25, 2019 / The cost of healthcare has been outpacing inflation. According to Investor's Business Daily, the U.S. soon will ''spend nearly 20% of its gross domestic ...

  • ACCESSWIRE5 months ago

    Four Healthcare Stocks Looking to Close Out a Strong Week

    Nearly every day, headlines are popping up surrounding these innovative companies in the healthcare industry as they tackle the prevalent need for qualitative care. Whereas other industries may have different core values and purposes, healthcare companies are tasked with keeping consumers healthy and amid that responsibility, if done correctly, lies the potential for lucrative opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Zosano Pharma Corporation (ZSAN), Achieve Life Sciences Inc (ACHV), and Aurora Cannabis Inc (ACB) represent four healthcare companies focused on the advancement of the global healthcare industry.

  • Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
    PR Newswire5 months ago

    Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting

    SEATTLE and VANCOUVER, British Columbia, Feb. 22, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced final data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisinicline in smokers. Study results will be presented today, Friday, February 22nd, at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting in San Francisco. The study evaluated the repeat-dose PK and PD effects of 1.5 mg and 3.0 mg cytisinicline in 26 healthy volunteer smokers when administered over the standard 25-day course of treatment.

  • Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
    PR Newswire5 months ago

    Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

    SEATTLE and VANCOUVER, British Columbia, Feb. 20, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period, with secondary analyses being conducted on smoking cessation rates, safety, and compliance.

  • Achieve Announces Update on Cytisinicline Clinical Development Program
    PR Newswire7 months ago

    Achieve Announces Update on Cytisinicline Clinical Development Program

    SEATTLE and VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update. The U.S. Food and Drug Administration (FDA) has confirmed that they are in agreement with Achieve's Initial Pediatric Study Plan, specifically, providing a full waiver for evaluating cytisinicline in a pediatric population. The reasons for the full waiver were based on the low numbers of children smoking under the age of 12 and the logistical difficulties of recruiting treatment-seeking smokers in the adolescent age group.

  • Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
    PR Newswire8 months ago

    Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update

    SEATTLE and VANCOUVER, British Columbia , Nov. 7, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...